Lung Cancer Detection. Results of a Randomized Prospective Study in Czechoslovakia
Overview
Affiliations
A randomized prospective study of lung cancer detection was begun in 1976 to evaluate semiannual screening by radiologic and sputum cytologic study in comparison to screening at a 3-year interval, and to no screening. In a high-risk population of 6364 men (aged 40 to 64 years), the initial prevalence of lung cancer was 0.28% (18 cases), the annual incidence was 0.35% per year (66 cases during 3 years), the proportion of Stage I cases was 31% (26/84), and Stage II was 17% (14/84), "curative" resections were 27% (23/84), and 5-year survival was 23% (19/84). The study confirmed the ability of radiologic screening to detect lung cancer at an earlier stage when treatment by resection can be accomplished. The fate of a high-risk population submitted to screening was better than that of a population with no screening where lung cancer was discovered by symptoms, accidental x-rays, or at autopsy. A matter of lesser importance was the frequency of screening. The absolute numbers of 5-year survivors detected by screening were practically the same for either compared screening frequency.
Duer E, Yang H, Robinson S, Grigore B, Sandercock J, Snowsill T Diagn Progn Res. 2023; 7(1):26.
PMID: 38072977 PMC: 10712083. DOI: 10.1186/s41512-023-00162-0.
Effective lung cancer control: An unaccomplished challenge in cancer research.
Panakkal N, Lekshmi A, Saraswathy V, Sujathan K Cytojournal. 2023; 20:16.
PMID: 37681073 PMC: 10481856. DOI: 10.25259/Cytojournal_36_2022.
Soukiasian H, Leung A, Imai T, Bose S, Kim S, Mosenifar Z JTCVS Open. 2023; 13:389-410.
PMID: 37063144 PMC: 10091303. DOI: 10.1016/j.xjon.2022.11.018.
Artificial Intelligence in Lung Cancer Imaging: Unfolding the Future.
Cellina M, Ce M, Irmici G, Ascenti V, Khenkina N, Toto-Brocchi M Diagnostics (Basel). 2022; 12(11).
PMID: 36359485 PMC: 9689810. DOI: 10.3390/diagnostics12112644.
Advances in lung cancer screening and early detection.
Li C, Wang H, Jiang Y, Fu W, Liu X, Zhong R Cancer Biol Med. 2022; .
PMID: 35535966 PMC: 9196057. DOI: 10.20892/j.issn.2095-3941.2021.0690.